iCAD Inc (NASDAQ:ICAD) – Research analysts at Zacks Investment Research lifted their FY2020 earnings per share (EPS) estimates for iCAD in a research report issued on Tuesday, May 14th. Zacks Investment Research analyst B. Marckx now forecasts that the technology company will earn $0.05 per share for the year, up from their previous forecast of $0.03.
Separately, ValuEngine raised iCAD from a “hold” rating to a “buy” rating in a report on Saturday, March 30th.
Shares of ICAD opened at $5.83 on Thursday. The company has a market cap of $98.12 million, a PE ratio of -15.34 and a beta of 1.34. iCAD has a 1 year low of $2.42 and a 1 year high of $6.32. The company has a debt-to-equity ratio of 1.63, a quick ratio of 1.48 and a current ratio of 1.60.
iCAD (NASDAQ:ICAD) last issued its quarterly earnings data on Tuesday, May 7th. The technology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.08. The business had revenue of $6.77 million for the quarter, compared to analysts’ expectations of $6.10 million. iCAD had a negative return on equity of 47.63% and a negative net margin of 36.24%.
A number of large investors have recently added to or reduced their stakes in ICAD. Renaissance Technologies LLC raised its holdings in iCAD by 13.4% during the 3rd quarter. Renaissance Technologies LLC now owns 577,960 shares of the technology company’s stock valued at $1,682,000 after buying an additional 68,200 shares during the period. FNY Investment Advisers LLC purchased a new stake in iCAD during the 4th quarter valued at $75,000. Columbia Pacific Advisors LLC purchased a new stake in iCAD during the 4th quarter valued at $74,000. Advisor Group Inc. raised its holdings in iCAD by 96,087.0% during the 4th quarter. Advisor Group Inc. now owns 22,123 shares of the technology company’s stock valued at $82,000 after buying an additional 22,100 shares during the period. Finally, IHT Wealth Management LLC purchased a new stake in iCAD during the 4th quarter valued at $48,000. Institutional investors own 17.18% of the company’s stock.
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Recommended Story: How to find the components of the quick ratio